EUVIMEDEUVIMED entdecken
Open Access

PMVK drives hepatocarcinogenesis via SP1 phosphorylation–mediated lipid metabolic reprogramming

Ruiyang Liu iD, Caini Huang, Zhijie Xu, Fuyuan Xu, Xinyi Wen, Zhiju Zhao iD, Fei Xiao iD

Science Advances · 26.06.2026 · 12 (26)

DOI: 10.1126/sciadv.aed8866 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 26.06.2026. Verfasst von Ruiyang Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China. Hauptthemen laut MEDLINE: Sp1 Transcription Factor, Liver Neoplasms, Carcinoma, Hepatocellular, Lipid Metabolism. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Guangdong Hong Kong Macao University Joint Laboratory of Interventional Medicine Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic reprogramming is a hallmark of cancer, yet the critical drivers and mechanisms in hepatocellular carcinoma (HCC) remain incompletely understood. Through a metabolism-focused CRISPR screen, we identified phosphomevalonate kinase (PMVK), a mevalonate pathway enzyme, as a key regulator of HCC stemness and progression. PMVK directly phosphorylates the transcription factor SP1 at Thr 355 , which enhances SP1’s DNA binding affinity and promotes its interaction with the master lipid regulator SREBP1/2, driving a transcriptional program essential for de novo cholesterol and fatty acid synthesis. Clinically, PMVK levels are positively correlated with phospho-SP1 (Thr 355 ) levels and predicate poor prognosis in patients with HCC. Functionally, we demonstrate that genetic or pharmacologic inhibition of the PMVK-SP1 axis, including using the SP1 inhibitor mithramycin A (MTA), significantly suppresses HCC tumorigenesis. In conclusion, our findings uncover the PMVK-SP1 axis as a central driver of lipid metabolic reprogramming and hepatocarcinogenesis, highlighting it as a compelling therapeutic target in HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sp1 Transcription FactorLiver NeoplasmsCarcinoma, HepatocellularLipid MetabolismPhosphotransferases (Phosphate Group Acceptor)CarcinogenesisMetabolic ReprogrammingPhosphorylationHumansAnimalsGene Expression Regulation, NeoplasticPlicamycinCell Line, Tumor

Substanzen

Sp1 Transcription FactorPhosphotransferases (Phosphate Group Acceptor)Plicamycin

Autor:innen und Institutionen

  • Department of Infectious Diseases, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
  • Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
  • Guangdong-Hong Kong-Macao University Joint of Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
  • Key Laboratory for Regenerative Medicine, Ministry of Education, School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Kashi Guangdong Institute of Science and Technology, The First People's Hospital of Kashi, Kashi, Xinjiang Uyghur Autonomous Region, China.
  • State Key Laboratory of Anti-Infective Drug Development, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, Guangdong Province, China.

ORCID-Profile: Ruiyang Liu, Zhiju Zhao, Fei Xiao

Förderung

  • National Natural Science Foundation of China
  • Guangdong Hong Kong Macao University Joint Laboratory of Interventional Medicine Foundation of Guangdong Province

Zitieren

APA

Liu, R., Huang, C., Xu, Z., Xu, F., Wen, X., Zhao, Z., & Xiao, F. (2026). PMVK drives hepatocarcinogenesis via SP1 phosphorylation–mediated lipid metabolic reprogramming. Science Advances, 12(26). https://doi.org/10.1126/sciadv.aed8866

Vancouver

Liu R, Huang C, Xu Z, Xu F, Wen X, Zhao Z, et al. PMVK drives hepatocarcinogenesis via SP1 phosphorylation–mediated lipid metabolic reprogramming. Science Advances. 2026;12(26). doi:10.1126/sciadv.aed8866

BibTeX
@article{Liu2026,
  author = {Liu, Ruiyang and Huang, Caini and Xu, Zhijie and Xu, Fuyuan and Wen, Xinyi and Zhao, Zhiju and Xiao, Fei},
  title = {PMVK drives hepatocarcinogenesis via SP1 phosphorylation–mediated lipid metabolic reprogramming},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {26},
  doi = {10.1126/sciadv.aed8866}
}
Kostenlos starten →